WallStreetZenWallStreetZen

NASDAQ: BVS
Bioventus Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BVS

Based on 1 analyst offering 12 month price targets for Bioventus Inc

Min Forecast
$15.00+121.57%
Avg Forecast
$15.00+121.57%
Max Forecast
$15.00+121.57%

Should I buy or sell BVS stock?

Based on 1 analyst offering ratings for Bioventus Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their BVS stock forecasts and price targets.

BVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-17

1 of 1

Forecast return on equity

Is BVS forecast to generate an efficient return?

Company
44.36%
Industry
23.03%
Market
66.57%
BVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BVS forecast to generate an efficient return on assets?

Company
9.5%
Industry
12.11%
BVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BVS earnings per share forecast

What is BVS's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$0.66
Avg 2 year Forecast
$0.73
Avg 3 year Forecast
$0.80

BVS revenue forecast

What is BVS's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$566.4M-0.22%
Avg 2 year Forecast
$596.1M+5.01%
Avg 3 year Forecast
$625.8M+10.23%
BVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BVS revenue growth forecast

How is BVS forecast to perform vs Medical Devices companies and vs the US market?

Company
2.47%
Industry
8.16%
Market
10%
BVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BVS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BVS$6.77$15.00+121.57%Strong Buy
AVNS$12.21N/AN/A
KIDS$21.37$35.83+67.68%Strong Buy
RXST$12.67$26.14+106.34%Buy
BFLY$1.96$4.00+104.08%Strong Buy
View Top Medical Device Stocks

Bioventus Stock Forecast FAQ

Is Bioventus Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BVS) stock is to Strong Buy BVS stock.

Out of 1 analyst, 1 (100%) are recommending BVS as a Strong Buy, 0 (0%) are recommending BVS as a Buy, 0 (0%) are recommending BVS as a Hold, 0 (0%) are recommending BVS as a Sell, and 0 (0%) are recommending BVS as a Strong Sell.

If you're new to stock investing, here's how to buy Bioventus stock.

What is BVS's earnings growth forecast for 2025-2027?

(NASDAQ: BVS) Bioventus's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 20.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.72%.

Bioventus's earnings in 2025 is -$31,609,000.On average, 1 Wall Street analyst forecast BVS's earnings for 2025 to be $54,215,269, with the lowest BVS earnings forecast at $54,215,269, and the highest BVS earnings forecast at $54,215,269. On average, 1 Wall Street analyst forecast BVS's earnings for 2026 to be $59,965,373, with the lowest BVS earnings forecast at $59,965,373, and the highest BVS earnings forecast at $59,965,373.

In 2027, BVS is forecast to generate $65,715,478 in earnings, with the lowest earnings forecast at $65,715,478 and the highest earnings forecast at $65,715,478.

What is BVS's revenue growth forecast for 2025-2027?

(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 2.47% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.

Bioventus's revenue in 2025 is $567,699,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $46,529,022,471, with the lowest BVS revenue forecast at $46,529,022,471, and the highest BVS revenue forecast at $46,529,022,471. On average, 1 Wall Street analysts forecast BVS's revenue for 2026 to be $48,968,709,577, with the lowest BVS revenue forecast at $48,968,709,577, and the highest BVS revenue forecast at $48,968,709,577.

In 2027, BVS is forecast to generate $51,405,932,353 in revenue, with the lowest revenue forecast at $51,405,932,353 and the highest revenue forecast at $51,405,932,353.

What is BVS's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BVS) forecast ROA is 9.5%, which is lower than the forecast US Medical Devices industry average of 12.11%.

What is BVS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BVS price target, the average BVS price target is $15.00, with the highest BVS stock price forecast at $15.00 and the lowest BVS stock price forecast at $15.00.

The Wall Street analyst predicted that Bioventus's share price could reach $15.00 by Mar 17, 2026. The average Bioventus stock price prediction forecasts a potential upside of 121.57% from the current BVS share price of $6.77.

What is BVS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BVS) Bioventus's current Earnings Per Share (EPS) is -$0.48. On average, analysts forecast that BVS's EPS will be $0.66 for 2025, with the lowest EPS forecast at $0.66, and the highest EPS forecast at $0.66. On average, analysts forecast that BVS's EPS will be $0.73 for 2026, with the lowest EPS forecast at $0.73, and the highest EPS forecast at $0.73. In 2027, BVS's EPS is forecast to hit $0.80 (min: $0.80, max: $0.80).

What is BVS's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BVS) forecast ROE is 44.36%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.